plans to share additional data about the Alzheimer’s disease treatment it’s developing with Biogen Inc.
at an eagerly anticipated presentation this week. The Japanese drugmaker is set to present the findings from a Phase 3 clinical trial evaluating lecanemab as a treatment for people with early Alzheimer’s disease on Tuesday at 4:50 p.m. Pacific time at the Clinical Trials in Alzheimer’s Disease (CTAD) annual meeting in San Francisco.
Preliminary clinical data show that lecanemab can slow cognitive decline in patients in the early stages of Alzheimer’s diseases by 27%, a finding that sent shares in the two companies soaring — and raised the hopes of healthcare providers and of families of people with the neurological disease. Eli Lilly & Co.’s
donanemab is currently in late-stage clinical trials, as well. “There remains a healthy amount of debate into CTAD in terms of the details/nuances of lecanemab’s clinical profile, which could have a meaningful impact on reimbursement and potential competitive differentiation, should [Lilly’s] donanemab be successful,” UBS Securities analyst Colin Bristow wrote in an investor note on Monday. Wall Street analysts will look at the data for lecanemab to learn how long the drug remains effective, what the reported deaths of two patients in the trial mean and whether certain high-risk patients should be excluded from receiving the drug if it is approved. (Science magazine reported Sunday that a 65-year-old woman in the study died from a brain hemorrhage “that some researchers link to the drug.”) “It is plausible that receiving a beta-amyloid antibody like lecanemab could increase susceptibility to intracranial hemorrhage from blood thinners (as was also the case with the first reported lecanemab death …) or if there are predisposing factors such as amyloid angiopathy or pre-existing microhemorrhages,” RBC Capital Markets analyst Brian Abrahams told investors on Monday. Howe …